Prognostic Factors of Maxillary Sinus Malignancies

Nazar, Gonzalo; Rodrigo, Juan P.; Llorente, José Luís; Baragaño, Lucia; Suárez, Carlos

doi:10.1177/194589240401800408

Cited by 39 publications

(24 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With advances in treatment techniques, the survival outcomes in patients with sinonasal malignancies have improved over time . However, orbital invasion remains a negative prognostic factor . Aggressive methods, such as orbital exenteration, may not result in a better survival outcome .…”

Section: Discussionmentioning

confidence: 99%

“…14 However, orbital invasion remains a negative prognostic factor. 4,8,10 Aggressive methods, such as orbital exenteration, may not result in a better survival outcome. 5 In recent years, the combination of orbital preservation and chemoradiotherapy has resulted in 5-year OS rates ranging from 41% to 54%.…”

Section: Discussionmentioning

confidence: 99%

“…Sinonasal malignancies are usually diagnosed at a locally advanced stage . They commonly invade the orbit, with a frequency of up to 80% . Orbital invasion is widely accepted as a negative prognostic factor in sinonasal malignancies .…”

mentioning

confidence: 99%

“…They commonly invade the orbit, with a frequency of up to 80% . Orbital invasion is widely accepted as a negative prognostic factor in sinonasal malignancies . The orbital periosteum acts as a barrier against invasion and is recognized as an “anatomic landmark” of orbital exenteration over time .…”

mentioning

confidence: 99%

See 3 more Smart Citations

Management of orbital invasion in sinonasal squamous cell carcinoma: 15 years’ experience

Tian

Zhu

et al. 2019

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Background This study was intended to review our management strategy for sinonasal squamous cell carcinomas (SNSCCs) with orbital invasion and to explore the role of radiotherapy in orbital preservation. Methods We retrospectively analyzed 93 SNSCC patients with orbital invasion who underwent radiotherapy with or without surgery over the past 15 years. The degree of orbital invasion was classified into 3 grades. Results Eighty‐eight patients presented with T4 tumors and 36 had grade III orbital invasion. Seventy‐two patients received surgery plus radiation and 67 received platinum‐based chemotherapy. The median follow‐up for surviving patients was 60 months. Five‐year overall survival (OS) for the whole group was 57.4%. The patients treated with surgery plus radiation had a 5‐year survival rate of 62.2% and orbital preservation was feasible in 90.3% of cases. Twenty‐one patients with SNSCCs that extended into the extraocular muscles or eye globe also underwent orbital preservation. Five‐year locoregional relapse‐free survival (LRFS) was 69.5% for patients treated with orbital preservation and 57.1% for those treated with orbital exenteration, indicating no statistical difference. Five‐year survival, 5‐year progression‐free survival (PFS), and 5‐year distant metastasis‐free survival (DMFS) were similar between groups. Grade III orbital invasion was independently associated with shorter OS, LRFS, PFS, and DMFS. Conclusion Orbital invasion in grade III was associated with the worst survival outcomes. Invasion of either the extraocular muscles or eye globe is not a contraindication for eye‐sparing surgery. Preoperative chemoradiation continues to offer hope to patients with a strong desire to preserve their eyes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Management of orbital invasion in sinonasal squamous cell carcinoma: 15 years’ experience

Tian

Zhu

et al. 2019

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…14 In the current study, the pathologic down-staging of the primary tumor in the patients treated with ICT followed by surgical resection was evaluated. In 10 cases of T4 tumors, pathologic down-staging after the ICT was identified in nine cases with one pathologic CR.…”

Section: Resultsmentioning

confidence: 99%

Treatment outcome of maxillary sinus cancer

et al. 2009

View full text Add to dashboard Cite

The standard treatment in the early stage of maxillary sinus cancer is surgical resection followed by postoperative radiation therapy. However, for locally advanced maxillary sinus cancer, a multimodality treatment approach is strongly recommended to improve the survival rate and quality of life of the patient. We determined the treatment outcomes of induction chemotherapy, concurrent chemoradiation therapy, and surgical resection for locally advanced maxillary sinus cancer. Forty-four patients with locally advanced maxillary sinus cancer, who had been treated between January 1990 and April 2008 at Kangnam St. Mary's Hospital, were retrospectively analyzed. The objective response rates were 70%, 53%, and 57% in the intra-arterial induction chemotherapy, intravenous induction chemotherapy, and concurrent chemoradiation therapy groups, respectively. The orbital preservation rates were 83%, 100%, and 75% in the intra-arterial induction chemotherapy, intravenous induction chemotherapy, and surgical resection groups, respectively. In seven of nine patients in whom the orbit could be preserved after induction chemotherapy, the primary tumors were removed completely. However, although the orbits were preserved in three patients who underwent surgical resection as a primary treatment, all three cases were confirmed to be incomplete resections. We found that active induction chemotherapy for locally advanced cancer of the maxillary sinus increased the possibility of complete resection with orbital preservation as well as tumor down-staging.

show abstract

Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma

López¹,

Llorente²,

Oviedo³

et al. 2011

Cancer

View full text Add to dashboard Cite

BACKGROUND: Sinonasal squamous cell carcinomas (SNSCCs) are rare tumors with no etiologic link to tobacco or alcohol, as opposed to other squamous cell carcinomas of the head and neck. Despite improvements in the field of surgery and radiotherapy, patients with these tumors still face a very unfavorable prognosis, partly because of their localization in a complex anatomic area, which has special relevance for surgery and postoperative treatment. Therefore, there is a need for new therapeutic possibilities for patients with these tumors. METHODS: Gene copy numbers of epidermal growth factor receptor (EGFR) and v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2) were analyzed by fluorescence in situ hybridization and multiplex ligand-dependent probe amplification, and protein expression was evaluated by immunohistochemistry in 54 SNSCC specimens. The results were correlated with clinicopathologic and follow-up data. RESULTS: EGFR gene copy number increases were observed in 20 of 45 tumors (44%), and 21 of 54 tumors (39%) had EGFR protein overexpression. Eight of 38 tumors (21%) had ERBB2 copy number increases, and 4 of 54 tumors (7%) exhibited elevated protein expression levels. Both copy number increases and protein overexpression of EGFR and ERBB2 were mutually exclusive. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations were absent in 37 tumors that were analyzed. CONCLUSIONS: A substantial proportion of SNSCCs carried alterations in EGFR or ERBB2. Together with the absence of KRAS mutations, these findings indicate that therapies targeting these molecules may be promising additions to the therapeutic options for patients with SNSCC.

show abstract

Prognostic Factors of Maxillary Sinus Malignancies

Abstract: Advanced T stage, base of skull involvement, orbital extension, and local recurrence are highly predictive of poor survival.

Cited by 39 publications

References 31 publications

Management of orbital invasion in sinonasal squamous cell carcinoma: 15 years’ experience

Management of orbital invasion in sinonasal squamous cell carcinoma: 15 years’ experience

Treatment outcome of maxillary sinus cancer

Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma

Contact Info

Product

Resources

About